Chongqing Pharmaceutical Holding H1 Revenue RMB40.13 Billion, Net Profit RMB254 Million, 231 DTP Pharmacies

On the evening of August 25, Chongqing Pharmaceutical Holding released its 2026 semi-annual report. During the reporting period, the company achieved operating revenue of RMB40.13 billion, total profit of RMB418 million, net profit attributable to shareholders of RMB254 million, and net profit after deducting non-recurring items of RMB243 million.

In the first half, the company's sales scale ranked among the top five in the pharmaceutical distribution industry. The Chongqing headquarters region generated operating revenue of RMB13.747 billion, accounting for 34.25%; subsidiaries outside Chongqing generated revenue of RMB26.385 billion, accounting for 65.75%. The company's business covers 30 provinces and cities and 178 prefecture-level cities.

The company deepened its 'wholesale-retail integration' strategy, opening 6 new DTP pharmacies, with DTP business growing about 35% year on year. As of the end of the reporting period, it had 231 DTP specialty pharmacies across 24 regions. In logistics, it completed the first and second phase acceptance of imported distribution logistics, advanced projects such as Sichuan Logistics Phase II and Tianjin Logistics, and implemented renovation and expansion projects in Chongqing, Ningxia, and Gansu. In the first half, it added 22 provincial-level logistics bases and warehousing centers, adding nearly 30,000 square meters of warehousing area. As of the end of the period, it had 11 self-built provincial-level modern logistics bases and 184 warehousing centers at various levels, with total warehousing area of nearly 800,000 square meters.

The medical device segment added 51 companies to conduct business. The traditional Chinese medicine segment's two subsidiaries were selected for 22 varieties, and added 2 smart TCM pharmacies. The online pharmaceutical e-commerce platforms 'Chongqing Pharmaceutical Cloud' and 'Yaodongdong' saw operating performance grow 80% year on year. Among emerging businesses, medical aesthetics grew 45%; special medical food business added cooperation with 5 hospitals; radiopharmaceutical business added 1 qualification, bringing the total to 6, with revenue up 67% year on year.

The associated industrial subsidiary Chongqing Yaoyou achieved operating revenue of RMB2.238 billion and net profit attributable to shareholders of RMB432 million. Chongqing Yaoyou invests 5% of its annual operating revenue in R&D, and over 60% of its products have dual filings in China and the US. Its APIs have passed European and American cGMP certification, with 75% sold to Europe and the US; its formulations have passed Canadian cGMP certification, and its solid dosage forms have passed US cGMP certification. During the reporting period, the company invested in, screened, cultivated, and filed new products in the digestive metabolism and blood system fields. As of the disclosure date, 4 products were approved, of which 3 have been commercialized.